IntelliPharmaCeutics International (TSXV:IPCI) LT-Debt-to-Total-Asset : 0.00 (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. IntelliPharmaCeutics International's long-term debt to total assests ratio for the quarter that ended in Aug. 2023 was 0.00.

IntelliPharmaCeutics International's long-term debt to total assets ratio stayed the same from Aug. 2022 (0.00) to Aug. 2023 (0.00).

IntelliPharmaCeutics International LT-Debt-to-Total-Asset Historical Data

The historical data trend for IntelliPharmaCeutics International's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International LT-Debt-to-Total-Asset Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

IntelliPharmaCeutics International LT-Debt-to-Total-Asset Calculation

IntelliPharmaCeutics International's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Nov. 2022 is calculated as

LT Debt to Total Assets (A: Nov. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Nov. 2022 )	/	Total Assets (A: Nov. 2022 )
	=	0	/	1.927
	=	0.00

IntelliPharmaCeutics International's Long-Term Debt to Total Asset Ratio for the quarter that ended in Aug. 2023 is calculated as

LT Debt to Total Assets (Q: Aug. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Aug. 2023 )	/	Total Assets (Q: Aug. 2023 )
	=	0	/	2.111
	=	0.00

IntelliPharmaCeutics International (TSXV:IPCI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

IntelliPharmaCeutics International LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines